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Summary Cyclooxygenase (COX)-2 is one of two isoforms of COX that is the rate-limiting enzyme
in the production of prostaglandin from arachidonic acid. It is induced by stimuli such as mitogens,
cytokines, growth factors and tumor promoters, and has been elucidated to be up-regulated not
only at the sites of inflammation but also in various cancer tissues such as colon, stomach, breast,
lung and head and neck including oral cavity. Overexpression of COX-2 is known to inhibit apoptosis
and immune surveillance, promote angiogenesis, increase cancer invasiveness and metastasis.
Therefore, COX-2 is considered to be strongly involved in carcinogenesis and tumor growth. In fact,
immunohistochemical and Western blot analyses in oral precancerous and cancerous lesions
demonstrated that COX-2 expression is increased from epithelial dysplasia to squamous cell
carcinoma through carcinoma in situ, with the elevation of cell proliferating activity. The patients
with overexpression of COX-2 showed poor prognosis and their overall 5-year survival rate was
decreased. Inhibition of COX-2 activity with selective COX-2 inhibitors or antisense RNA resulted in
suppression of tumor cell growth and invasion in vitro and prevention of oral carcinogenesis by
chemical carcinogens in animalmodels. In addition, combined use of selective COX-2 inhibitorswas
found to enhance synergistically the cytocidal effects of anti-cancer drugs and irradiation. From
these evidences, it is indicated that COX-2 becomes a potent molecular target for prevention and
therapy of oral cancer.
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58 M. Urade1. Introduction
Oral cancer is 1 of the 10 most frequent cancers in the world
[1]. It accounts for approximately 2% of all cancers and 1% of
all cancer deaths [2]. Squamous cell carcinoma (SCC) is the
most common malignant tumor of the oral cavity, accounting
for over 90% of the malignant neoplasms in this region [3],
and is thought to arise from a progressive dysplasia of the oral
mucosa. The incidence of regional lymph node metastasis in
oral SCC is comparatively high. The outcome of the patients
with lymph node metastasis is poor, with overall 5-year
survival rate of approximately 25% [4]. Despite of recent
advances in diagnosis and the surgical, radiotherapeutic, and
chemotherapeutic treatments of oral cancer, 5-year survival
rate has improved only marginally [3]. Furthermore, recent
epidemiologic data indicated that the incidence of oral
cancer is increasing [2,5]. Therefore, the setting of new
molecular targets is necessary for diagnosis, prevention
and treatment of oral cancer.
In recent years, overexpression of cyclooxygenase (COX)-2
has been reported in a variety of cancers, including those
arising in the colon [6—8], stomach [9], breast [10], lung [11],
esophagus [12], pancreas [13], urinary bladder [14], prostate
[15] and head and neck [16—18]. COX is the rate-limiting
enzyme in the production of prostaglandin from arachidonic
acid [19]. Two isoforms of the COX enzyme exist, COX-1 and
COX-2, and they have been postulated to be target molecules
for non-steroidal anti-inflammatory drugs (NSAIDs). COX-1 is
constitutively expressed in most tissues and appears to be a
housekeeping enzyme responsible for various physiological
functions, such as cytoprotection in the stomach, vasodila-
tion in the kidney, and production of pro-aggregatory pros-
tanoid thromboxane by platelet. On the other hand, COX-2 is
induced by stimuli such as mitogens, cytokines, growth
factors and tumor promoters, and has been elucidated to
be involved in cancer development and pathogenesis such as
apoptosis [20], immune surveillance [21], angiogenesis [22],
invasion and metastasis [23], and cell differentiation (Fig. 1)Figure 1 Pathway of prostanoid synthesis from arachidonic acid, an
acid is released from membrane phospholipid by phospholipase A2. C
followed by conversion to PGH2 into other PG isoforms or thromboxan
a variety of biologic activities via its EP receptors.[24]. In this review, the relations among expression of COX-2
and carcinogenesis of the head and neck region including oral
cavity, malignant phenotype and prognosis of the patients are
focused. In addition, the possibility of COX-2 as a potent
molecular target for prevention and therapy of oral cancer is
discussed.
2. COX-2 expression in precancerous and
cancerous lesions of the head and neck
including oral cavity
Initial observations for overexpression of COX-2 in precan-
cerous and cancerous lesions were done in colorectal ade-
nomas and carcinomas [6—8]. This was based on the
epidemiological studies that the relative risk for colorectal
cancer was reduced by a 40-50% in persons who regularly use
aspirin and other NSAIDs [25—27]. Since then, overexpression
of COX-2 has been demonstrated in various cancer tissues,
mainly in adenocarcinomas. In these studies, COX-2 protein
was primarily distributed from the cytoplasmic perinuclear
region to the cytoplasmic matrix of tumor cells. With respect
to head and neck cancer, Chan et al. [16] have first reported
the up-regulation of COX-2 in head and neck squamous cell
carcinoma (HNSCC). They found by quantitative reverse
transcription-PCR that mean levels of COX-2 mRNA were
increased by nearly 150-fold in HNSCC (n = 24) compared
with normal oral mucosa (n = 17), and normal-appearing
epithelium adjacent to SCC (n = 10) showed about a 50-fold
increase of COX-2 mRNA compared with normal oral mucosa.
Immunoblotting and immunohistochemical analyses gave the
supportive results. We have also demonstrated increased
expression of COX-2 in human salivary gland tumors including
adenomas (SGA) and carcinomas (SGC) [17]. COX-2 protein
was detected in 27 of 30 SGA (90%), except for three myoe-
pitheliomas, and in all cases of SGC (100%) at various inten-
sities and in various fashions. Thirteen SGA (43%) and 36 SGC
(90%) showed strong COX-2 immunoreactivities. These find-d the involvement of COX-2 in cancer development. Arachidonic
OX-1 or COX-2 converts arachidonic acid to prostaglandin (PG) G2
e (TX) A2. Among them, PGE2 is the major prostanoid and exhibits
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tumors by Eberhart et al. [6]. When compared COX-2 expres-
sion between SGC and HNSCC, the intensity of COX-2 expres-
sion was clearly lower in HNSCC than in SGC. Hida et al. [11]
reported a similar result that more than two-thirds of ade-
nocarcinomas in the lung showed overexpression of COX-2
whereas SCCs of the lung were detected infrequent and low
expression. They speculated that the increased COX-2
expression might be a characteristic of human cancers
derived from glandular epithelium.
Head and neck cancer including oral cancer is considered
to develop by accumulated genetic alterations [28—30], and
the major pathway is cancerization from precancerous
lesions such as intraepithelial dysplasia in oral leukoplakia
and erythroplakia. Shibata et al. [31] examined COX-1 and -2
expression by Western blot and immunohistochemical ana-
lyses for 65 dysplasias and 50 SCCs, and reported that the
labeling indices for COX-1 and -2 were higher in dysplasias
than in SCCs and those of COX-2 but not COX-1 correlated
with the histological grade of dysplasias, being highest in the
severe dysplasias. Also, they stated that COX-2 expression
was significantly inversely correlated with the histological
differentiation of the SCCs. From these results, they con-
cluded that the expression of COX-1 and -2 is correlated with
early stage tumorigenesis and cellular differentiation of SCCs
in oral dysplasia-carcinoma sequence. Recently, we have
examined the expressions of COX-2 and DNA topoisomerase
(DNA-Topo) IIa as an index of cell proliferating activity
immunohistochemically for 60 intraepithelial dysplasias
(IEDs), 12 carcinomas in situ (CISs), 72 SCCs, 10 undifferen-
tiated carcinomas (UCs), and 10 epithelial hyperplasias
(EHPs) in the oral mucosa and found that 41% of IEDs, 67%Figure2 COX-2expression andDNA-Topo IIa labeling index in oral pre
percentage of COX-2-positive (black bar) and DNA-Topo IIa-positive
counting a total 2000 cells in 10 randomly selected fields of each s
epithelium;EHP, epithelial hyperplasia; IED, intraepithelial hyperplasia
invasive squamous cell carcinoma;W-SCC,well-differentiated squamou
carcinoma; P-SCC, poorly differentiated squamous cell carcinoma; Uof CISs, 74% of SCCs and 86% of UCs demonstrated increased
COX-2 expression with elevated DNA-Topo IIa labeling index
(Figs. 2 and 3) [32]. Increased COX-2 expression correlated
with elevated DNA-Topo IIa labeling index, indicating that
COX-2 may contribute to malignant transformation and
tumor growth. A similar high COX-2 expression was observed
in EHPs, but DNA-Topo IIa labeling index was very low. In
contrast with Shibata’s paper, we observed no significant
difference in expression of COX-2 among mild, moderate
and severe dysplasia, and COX-2 expression was increased
as tumor differentiation was decreased. Similar results that
there is no significant difference of COX-2 expression in the
degrees of intraepithelial dysplasia were reported by Renko-
nen et al. [33] and Sudbo et al. [34] In particular, Sudbo et al.
stated that COX-2 expression was correlated to DNA content
(DNA aneuploidy) as a genetic risk marker of oral cancer. With
respect to COX-1 expression in HNSCC, we did not find the
overexpression in cancer tissues. COX-1 protein was diffusely
stained in both dysplastic and carcinoma cells, and mainly
observed in lymphocytes, macrophages, vascular endothelial
cells and striated muscles [32]. Therefore, it is needed to
accumulate more evidences for COX-1 expression in oral
precancerous and cancerous lesions.
The relationship between COX-2 expression and tumor
differentiation in SCCs is still controversial. In the lung [11],
esophagus [35] and larynx [36], it was reported that COX-2
expression was elevated in well-differentiated carcinomas
more than in poorly differentiated carcinomas. On the other
hand, it was reported in SCCs of the tongue [33] and of the
esophagus [37] that more undifferentiated carcinoma (histo-
logical grade III) had significantly stronger COX-2 expression
than grade I or II cases. In our recent study, we have reportedcancerous and cancerous lesions andoutcomeof the patients. The
cells (hatched bar) were determined immunohistochemically by
ection examined at 400 magnification. NSE, normal squamous
; CIS, carcinoma in situ; SCC, sqamous cell carcinoma;EISCC, early
s cell carcinoma;M-SCC,moderately differentiated squamous cell
C, undifferentiated carcinoma (cited from Ref. [32]).
Figure 3 Relationship between expression of COX-2 protein and DNA-Topo IIa labeling index in oral precancerous, cancerous and
hyperplastic lesions. (^) NSE; (^) EHP; (~) mild IED; (~) moderate IED; (5) severe IED; (!) CIS; (&) EISCC; (*) W-SCC; (*) M-SCC;
( ) P-SCC; (&) UC. Statistical significance was r = 0.74, p < 0.001 in x2 test (cited from Ref. [32]).
60 M. Uradethat treatment of human oral SCC25 cells with sodium buty-
rate, a differentiation-inducing agent, caused promotion of
cell differentiation and suppression of cell growth and COX-2
expression [38]. These findings supported our histological data
in tumor differentiation and COX-2 expression.
3. COX-2 expression and prognostic
significance in oral cancer
Accumulating evidences indicate that expression of COX-2 is
closely related to overall survival, along with prognostic
variables such as tumor size, tumor differentiation, lymph
node metastasis, and disease stage [39—44]. However, sev-
eral studies have reported that overexpression of COX-2 does
not significantly correlate with survival [36,45—48]. Whether
overexpression of COX-2 is associated with poor prognosis
thus remains controversial. Only 3 out of these previously
published studies were performed in patients with HNSCC.
Two of these studies, one in HNSCC by Gallo et al. [43] and the
other in oropharyngeal SCC by Chang et al. [44], reported
that COX-2 overexpression is related to poor survival,
whereas the other in laryngeal SCC by Ranelletti et al.
[36] found that the level of COX-2 negatively correlated with
both overall survival and relapse-free survival. Gallo et al.
[43] described in their study using 52 patients with HNSCC
that the most significant prognostic factors were presence of
lymph node metastasis, tumor vascularization associated
with expression of vascular endothelial growth factor (VEGF),
COX-2 expression and PGE2 levels. Chang et al. [44] reported
by the retrospective cohort study using 82 patients with SCCthat COX-2 was the most important predictor of poor survival
in multivariate analysis. In contrast, Ranelletti et al. [36]
described in their report studying 61 patients with laryngeal
SCC that the significant prognostic factors for relapse-free
and overall survivals were high histopathological grading,
lymph node involvement, low levels of COX-2 expression,
and high levels of EGFR expression. In our recent study [49],
we compared the expressions of COX-2 and DNA-Topo IIa
immunohistochemically between 80 patients who had oral
carcinoma with lymph node metastasis and 80 patients who
had oral carcinoma without lymph node metastasis. These
groups were matched with respect to sex, age, tumor site, T
category, tumor growth pattern, and tumor differentiation.
As a result, COX-2 expression in primary lesions was higher in
cases with lymph node metastasis than in those without
lymph node metastasis. An increase in tumor size was asso-
ciated with increased COX-2 expression. In most cases with
lymph node metastasis, COX-2 expression was higher in
metastatic lesions than in primary lesions. As COX-2 expres-
sion increased, the DNA-Topo IIa labeling index significantly
increased and the overall 5-year survival rate decreased
(Table 1, Fig. 4). Our results supported the hypothesis that
overexpression of COX-2 is associated with poor survival and
closely related to lymph node metastasis.
4. COX-2 expression and malignant
phenotypes in vitro
Overexpression of COX-2 causes excess production of pros-
taglandins, and induces an increase of cell proliferation and
Table 1 The percentage of COX-2-positive and DNA-Topo IIa-positive tumor cells in primary and metastatic lesions of oral carcinoma
Note: Statistical analysis was done by using the Fisher’s exact test (cited from Ref. [49]).
COX-2 as a molecular target for oral cancer 61decrease of apoptosis, mostly mediated by PGE2 and its
receptor EP1-4 (Fig. 1). This overexpression has been eluci-
dated to contribute to a variety of malignant phenotypes and
cancer pathogenesis. Tsujii et al. [20] reported that rat
intestinal epithelial cells transfected with a COX-2 expres-
sion vector were resistant to butyrate-induced apoptosis,
had elevated BCL2 protein expression, and increased adhe-
sion to extracellular matrix. These phenotypic changes were
reversed by sulindac sulfide (a COX inhibitor). They also
reported that human colon cancer cells (Caco-2) overexpres-
sing COX-2 produce prostaglandins, proangiogenic factors,
and stimulate both endothelial migration and tube forma-
tion. This effect was inhibited by antibodies to anti-angio-
genic factors, by NS-398 (a selective COX-2 inhibitor), and by
aspirin [22]. In addition, these cells acquired increased
invasiveness and metastatic potential compared with the
parental Caco-2 cells or the vector-transfected control cells,Figure 4 Overall 5-year survival of patients who had oral carcinoma
of COX-2 expression. (A) Survival of patients with or without lymph
intensities of COX-2 expression in primary lesions (n = 160). (C) Surviv
expression in primary lesions (n = 80). (D) Survival of patients with l
lesions (n = 80). (E) Survival of patients whose COX-2 expression inme
in primary lesions (n = 80). *p < 0.01, yp < 0.005, zp < 0.001, §p < 0via activation of metalloproteinase (MMP)-2 and membrane-
type metalloproteinase (MT-MMP). Increased invasiveness
was reversed by treatment with sulindac sulfide [23]. Huang
et al. [21] reported using A549 non-small cell lung cancer
cells that tumor-derived PGE2 modifies cytokine balance and
inhibits host immunity. Excess of PGE2 production by
increased expression of COX-2 in A549 cells caused up-reg-
ulation of interleukin (IL)-10 in lymphocytes and macro-
phages and down-regulation of IL-12 production in
macrophages via stimulation of IL-1b. Leong et al. [24]
reported that in human epidermis as well as in human
keratinocyte cultures, the COX-2 expression induces normal
keratinocyte differentiation.
In head and neck cancer, the significance of COX-2 expres-
sion in relation to tumor cell migration, invasion and metas-
tasis is not fully understood. A few in vitro studies have been
reported about COX-2 expression and cell proliferationwith or without lymph nodemetastasis or with various intensities
node metastasis (n = 160). (B) Survival of patients with various
al of patients without lymph node metastasis according to COX-2
ymph node metastasis according to COX-2 expression in primary
tastatic lesions was increased or decreased as comparedwith that
.0005 (cited from Ref. [49]).
62 M. Urade[50,51] and invasiveness of tumor cells [52] in HNSCC. Sumi-
tani et al. [50] reported that proliferation of oral SCC cell
lines NA and HSC-4 constitutively expressing COX-2 was
suppressed by NS-398 or COX-2 antisense oligonucleotide,
and Toyoshima et al. [51] reported that these inhibitors
induced G0/G1 cell arrest in NA cells via cyclin-dependent
kinase inhibitor p21. Kinugasa et al. [52] also reported that
NS-398 and COX-2 antisense oligonucleotide suppressed the
invasiveness of NA and HSC-4 cell lines in a Matrigel invasion
assay via down-regulation of MMP-2, MT1-MMP, and CD44. We
reported that cell growth of human tongue carcinoma cell
line SCC25 producing ample amount of PGE2 was inhibited by
celecoxib, a selective COX-2 inhibitor, and sulindac, but
exogenous addition of PGE2 resulted in an increased cell
growth of SCC25 even under the celecoxib-treated condition
[53]. Recently, we have reported that human KB carcinoma
cells transfected with COX-2 cDNA (KB/COX-2) showed a
similar growth rate in vitro compared to mock-transfected
control cells (KB/neo), but demonstrated significantly
increased ability of cell migration and invasion in wound
healing assay and Matrigel invasion assay, via up-regulation
of MMP-9, MMP-2 and MT1-MMPand down-regulation of tissue
inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 [54].
Reorganization of the actin cytoskeleton of the cell is the
primary mechanism of cell motility and is essential for most
types of cell migration. The actin reorganization is regulated
by Rho family small GTPases as Rho, Rac and Cdc42 [55].
Therefore, KB/COX-2 cells were examined for the Rho family
small GTPases by Western blot analysis. Consequently, KB/
COX-2 cells were found to show the elevated expression of
RhoA and Rac1 but not of Cdc42 as compared with KB/neo
cells [54].
5. COX-2 expression in oral carcinogenesis
in animal models and chemoprevention by
selective COX-2 inhibitors
Numerous experimental rodent models as well as epidemio-
logical studies have shown an inverse relationship between
NSAIDs intake and colon cancer development [25,56—58].
Clinical trials with NSAIDs in patients with familial adeno-
matous polyposis (FAP) have clearly demonstrated that NSAID
treatment caused regression of preexisting adenomas [59]. A
variety of studies for colon cancer in genetic animal models
including mutant mice with deletion of tumor suppresser
gene APC (adenomatous polyposis coli) [60] and carcino-
gen-treated animal models have also indicated a significant
reduction in tumor multiplicity by NSAID treatment [61].
Several animal studies concerning COX-2 expression in car-
cinogen-induced oral carcinogenesis and chemoprevention
with selective COX-2 inhibitors have been reported [62—65].
Shiotani et al. [62] and Yamamoto et al. [63] reported that 4-
nitroquinoline-1-oxide (4-NQO)-induced squamous cell dys-
plasias and carcinomas of the tongue in Fisher 344 rats
demonstrated increased COX-2 expression, and the feeding
of a selective COX-2 inhibitor, nimesulide or etodolac, to rats
decreased the incidence and multiplicity of tongue lesions in
a dose-dependent manner. Yoshida et al. [64] also reported
that nimesulide exerts chemopreventive ability against 4-
NQO-induced tongue tumorigenesis through inhibition of cell
proliferation activity in conjunction with modification ofCOX-2 and iNOS expression of the target lesions. We have
recently reported that COX-2 expression was increased dur-
ing hamster cheek pouch carcinogenesis with 9,10-dimethyl-
1,2-benzanthracene (DMBA), and the feeding of celecoxib, a
selective COX-2 inhibitor, delayed the onset of tumor forma-
tion and tumor growth, resulting in a prolonged survival of
animals. These effects were considered to be at least due to
increased induction of apoptosis in the tumor parenchyma
and significantly reduced angiogenesis in the stroma [65].
Similar data were shown by Nishimura et al. [66]. They
examined the anti-tumor effect of a selective COX-2 inhibi-
tor, JTE-522, in nude mice xenografted with human KB
carcinoma cells and indicated that the effect was caused
by anti-angiogenesis action, cell cycle arrest and inhibition of
telomerase activity of the tumor cells, resulting in an induc-
tion of apoptosis.
6. Possibility of clinical use of COX-2
inhibitors in treatment of oral cancer
In recent years, several preclinical studies for application of
selective COX-2 inhibitors in cancer treatment have been
performed concomitant with development of more selective
COX-2 inhibitors. As described before, single administration
of COX-2 inhibitors may be feasible to benefit the prevention
of colon carcinogenesis, especially for FAP patients, but it is
unlikely in application to precancerous lesions such as leu-
koplakia and erythroplakia for the prevention of oral carci-
nogenesis. In the clinical setting for head and neck cancer
including oral cancer, combination therapy of COX-2 inhibi-
tors with irradiation, anti-cancer drugs or inhibitors of epi-
dermal growth factor receptor (EGFR) may be possibly
applicable [67]. Amirghahari et al. [68] reported that NS-
398 demonstrated the radiosensitising effect on human
HNSCC cell line HEp3 via inhibition of radiation-induced
up-regulation of COX-2 protein expression. Raju et al. [69]
reported that celecoxib strongly enhanced the sensitivity of
human head and neck cancer cell line, HN-5, to radiation via
down-regulation of the expression of Ku70 protein and inhi-
bition of the kinase activity of DNA-PKs which are involved in
the double-stranded DNA-break repair. As another mechan-
ism, Gorski et al. [70] proposed that the anti-angiogenic
actions of COX-2 inhibitors produced rediosensitisation via
blockade of the VEGF stress response. Also, Milas et al. [71]
described that NSAIDs and selective COX-2 inhibitors
increased tumor radioresponse by restoring immunoreactiv-
ity. In inoperable/unresectable non-small lung cancer, a
phase I clinical trial of thoracic radiotherapy and concurrent
celecoxib has already been performed, and has proven the
safety of celecoxib administration and an encouraging out-
come of local progression-free survival [72].
Another potent therapy is the usage of COX-2 inhibitors in
combination with chemotherapy. COX-2 inhibitors have been
shown to potentiate the cytotoxic action of chemotherapeu-
tic agents in vitro and to improve their anti-tumor efficacy in
vivo. Hida et al. [73] reported that nimesulide induced
apoptosis and enhanced cytotoxicity of cisplatin and etopo-
side (VP-16) in lung cancer cells. Duffy et al. [74] reported
that COX-2 inhibitors showed a concentration-dependent
synergistic anti-tumor effect on human lung cancer cell lines
and a human leukemia line in combination with anthracycline
COX-2 as a molecular target for oral cancer 63(doxorubicin, daunorubicin and epirubicin), teniposide, eto-
poside and vincristine. We also reported that combination of
celecoxib with anti-cancer drugs, particularly doxorubicin,
vincristine and bleomycin, enhanced the cytotoxicity against
human head and neck carcinoma cell lines by increased
induction of apoptosis [53]. In in vivo studies, Hida et al.
[75] reported that combined use of JTE-522 and conventional
anti-cancer agents such as docetaxel and vinorelbine signifi-
cantly increased the efficacy of both in vitro and in vivo
growth inhibition in human lung cancer cells. Nakata et al.
[76] demonstrated that celecoxib enhanced the anti-tumor
efficacy of docetaxel and radiation on human A431 tumor
xenografts in mice, and that the greatest effect was achieved
when all three agents were combined. They suggested that
this improvement of anti-tumor efficacy is attributed to the
augmentation of apoptotic cell death. In patients with early-
stage non-small cell lung cancer, Altorski et al. [77] found
that the addition of celecoxib enhanced the response to
preoperative paclitaxel and carboplatin. Therefore, combi-
nation of COX-2 inhibitors with chemotherapeutic agents
and/or irradiation is considered to have a high potential
for oral cancer treatment.
Activation of epidermal growth factor receptor (EGFR)
has been linked to cancer. Expression of EGFR has been
documented to be deregulated in oral mucosa during head
and neck tumorigenesis and up-regulated in HNSCC [78]. Its
overexpression has been known to correlate with poor prog-
nosis in head and neck cancer [79]. Thus, EGFR is also a
therapeutic target for treatment of head and neck cancer.
Chen et al. [80] reported that combination of EGFR-selective
tyrosine kinase inhibitors AG1478 or ZD1839 (Iressa or gefti-
nib) with celecoxib either additively or synergistically inhib-
ited growth of five HNSCC cell lines by inducing G1 arrest and
apoptosis and suppressing capillary formation of endothe-
lium. They also reported that combination use of ZD1839 and
celecoxib significantly inhibited tumor growth in nude mice
xenografted with HNSCC cell line Tu212 [81]. Since Milas
et al. [82] found that anti-EGFR antibody (C225 or cetux-
imab) enhanced in vivo radioresponse in nude mice xeno-
grafted with human A431 carcinoma cells, combination
therapy of inhibitors of EGFR tyrosine kinase and COX-2 with
radiation and/or chemotherapeutic agents may become
useful strategies for treatment of oral cancer. In fact, it
has been reported as a chemoprevention trial that a phase III
randomized placebo-controlled study using COX-2 inhibitor
celecoxib and EGFR inhibitor EKB-569 in patients with aneu-
ploid dysplastic oral leukoplakia is in advanced planning
stages [83].
Selective COX-2 inhibitors are advantageous not only in
their high ability to enhance tumor response to radiother-
apy and chemotherapy but also in their lower association
with gastrointestinal complications, as compared with
standard NSAIDs including COX-1 inhibitors [84]. However,
it has recently been demonstrated that selective COX-2
inhibitors (e.g. rofecoxib, celecoxib) may be prothrombo-
tic and have a higher risk of myocardial infarction than
COX-1 inhibitors (e.g. naplofen) [85]. Although several
investigators have shown no significant difference between
them [86], the toxicity has been a concern in future clinical
study. At least, celecoxib has already been permitted in
clinical use in the United States, and also permitted in
Japan in June 2007.References
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